Table 3 Comparative results following insulin administration patients in Cohort 1, Cohort 2 (ITT) and Cohort 2 (PP) groups
Outcome | Cohort 1 N = 115 | Cohort 2 (ITT) N = 136 | P value* | Cohort 2 (PP) N = 103 | P value# |
|---|---|---|---|---|---|
Hypoglycaemia (BGL < 3.5 mmol/L) | 6 (5.2%) | 1 (0.7%) | < 0.03 | 0 (0%) | < 0.019 |
Mean BGL at time of FDG, mmol/L | 9.0 ± 2.6 | 8.6 ± 2.3 | NS | 8.6 ± 2.2 | NS |
Insulin dose prescribed, IU | 12 ± 4.1 | 11.1 ± 5.1 | NS | 10.5 ± 4.9 | NS |
Mean BGL decline, mmol/L | 7.1 ± 2.8 | 6.8 ± 2.9 | NS | 6.8 ± 2.9 | NS |
Achieved BGL ≤ 10.0 mmol/L, N (%) | 92 (80%) | 116 (85.3%) | 0.27 | 91 (88.3%) | 0.095 |
Repeat insulin dosage, N (%) | 17 (14.8%) | 10 (7.4%) | 0.06 | 7 (6.8%) | 0.06 |
Time from insulin to FDG injection, min | |||||
- Median | 136 | 108 | < 0.001 | 108 | < 0.001 |
- Range | 68–287 | 70–237 | 75–237 |